Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2012

View Archived Issues

New phase I data disclosed on KX2-391 in chemotherapy-naive bone-metastatic CRPC

OMP-59R5 well tolerated in phase I study

CalciMedica describes new class of immunomodulators

Clinical studies assess daily and twice-daily dosing of golvatinib

CHMP schedules hearing for Vivus' Qnexa MAA

Novel candidate cancer therapies created at Aurigene Discovery Technologies

Research alliance reached for carfilzomib and oprozomib

Phase III elagolix study begins in endometriosis

MebioPharm set to launch phase II/III MBP-426 trial

Portola Pharmaceuticals presents new SYK inhibitors

Dr. Reddy's Laboratories enters worldwide biosimilars collaboration

PharmaGap provides update on lead program

Roche expands gantenerumab trial in prodromal Alzheimer's disease

Preclinical study validates new target for resistant tumors

Phase I study evaluates peptide vaccine including cancer/testis antigens

Bayer designs novel guanylate cyclase activators

FDA sends complete response letter for ridaforolimus NDA

BioDiem to license new vaccine technology from Australian university

Kythera receives milestone payment from Bayer in ATX-101 collaboration

Research at U.S. university yields new anticancer agents

ProFibrix commences pivotal FINISH-3 study

Starpharma provides enrollment update for pivotal VivaGel studies

AVEO and Astellas planning new phase II study in RCC

Novel protein kinase inhibitors divulged

SDF-1 inhibition may limit transplant vasculopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...